Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model (Q42829229)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 March 2007

Language	Label	Description	Also known as
English	Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model	scientific article published on 6 March 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

2

object named as

Caroline Staib

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

4

object named as

Volker Erfle

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

author name string

Susanne El-Gogo

1

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Marcus Meyr

3

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Heiko Adler

6

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

language of work or name

0 references

publication date

6 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

3934-3945

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Old and new vaccine approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Host and viral genetics of chronic infection: a mouse model of gamma-herpesvirus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Unraveling immunity to gamma-herpesviruses: a new model for understanding the role of immunity in chronic virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Vaccination against murine gamma-herpesvirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immune evasion by gamma-herpesviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immune mechanisms in murine gammaherpesvirus-68 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Natural history of murine -herpesvirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

A battle for survival: immune control and immune evasion in murine gamma-herpesvirus-68 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Lung epithelial cells are a major site of murine gammaherpesvirus persistence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Long-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Gamma-herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Infectious clones of herpesviruses: a new approach for understanding viral gene function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Gene-based vaccines and immunotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Transient host range selection for genetic engineering of modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Mouse strain differences in the chemokine response to acute lung infection with a murine gammaherpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immunity, immunopathology and vaccines against HIV?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

An optimized CD8+ T-cell response controls productive and latent gammaherpesvirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Gamma-herpesvirus latency requires T cell evasion during episome maintenance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Effective vaccination against long-term gammaherpesvirus latency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

The limits of protection by "memory" T cells in Ig-/- mice persistently infected with a gamma-herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.054

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.02.054

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42829229&oldid=1971481863"